报价延迟最少15分钟:2025/09/14 16:50 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.93 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.14/0.22
|
|
企业价值
673.56M
|
| 资产负债 |
|
每股账面净值
1.84
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
482.04M
|
|
每股收益
3.61
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/14 16:50 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine. |
